📣 VC round data is live. Check it out!
- Public Comps
- Zhejiang Ausun
Zhejiang Ausun Valuation Multiples
Discover Zhejiang Ausun's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Phibro Animal Health, HBM Holdings, Guilin Sanjin, Avalyn Pharma and more.
Zhejiang Ausun Overview
About Zhejiang Ausun
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
Founded
2010
HQ

Employees
N/A
Website
Financials (FY)
EV
$1B
Valuation Multiples
Start free trialZhejiang Ausun Financials
Zhejiang Ausun reported last fiscal year revenue of $117M and EBITDA of $33M.
In the same fiscal year, Zhejiang Ausun generated $63M in gross profit, $33M in EBITDA, and $19M in net income.
Revenue (LTM)
Zhejiang Ausun P&L
In the most recent fiscal year, Zhejiang Ausun reported revenue of $117M and EBITDA of $33M.
Zhejiang Ausun is profitable as of last fiscal year, with gross margin of 54%, EBITDA margin of 28%, and net margin of 16%.
Financial data powered by Morningstar, Inc.
Zhejiang Ausun Stock Performance
Zhejiang Ausun has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Zhejiang Ausun's stock price is $1.40.
Zhejiang Ausun share price decreased by 0.1% in the last 30 days, and increased by 10.7% in the last year.
Zhejiang Ausun has an EPS (earnings per share) of $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -2.1% | -0.1% | -5.6% | 10.7% | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZhejiang Ausun Valuation Multiples
Zhejiang Ausun trades at 9.1x EV/Revenue multiple, and 32.7x EV/EBITDA.
EV / Revenue (LTM)
Zhejiang Ausun Financial Valuation Multiples
As of June 4, 2026, Zhejiang Ausun has market cap of $1B and EV of $1B.
Zhejiang Ausun has a P/E ratio of 60.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zhejiang Ausun Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Zhejiang Ausun Margins & Growth Rates
In the most recent fiscal year, Zhejiang Ausun reported gross margin of 54%, EBITDA margin of 28%, and net margin of 16%.
Zhejiang Ausun Margins
Zhejiang Ausun Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Zhejiang Ausun Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Zhejiang Ausun Competitors
Zhejiang Ausun competitors include Phibro Animal Health, HBM Holdings, Guilin Sanjin, Avalyn Pharma, MedinCell, Youcare Pharmaceutical, Marksans Pharma, TOWA Pharmaceutical, Bio-Thera Solutions and Aktis Oncology.
Most Zhejiang Ausun public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.4x | 1.3x | 10.2x | 7.6x | |||
| 5.2x | 4.4x | 8.4x | 8.1x | |||
| 3.3x | - | 10.2x | - | |||
| - | - | (11.1x) | (10.4x) | |||
| 39.9x | 29.6x | (91.1x) | (412.4x) | |||
| 2.9x | - | (968.9x) | - | |||
| 3.5x | 3.4x | 15.0x | 16.6x | |||
| 1.4x | 1.3x | 7.6x | 7.9x | |||
This data is available for Pro users. Sign up to see all Zhejiang Ausun competitors and their valuation data. Start Free Trial | ||||||
Investments by Zhejiang Ausun
Zhejiang Ausun has invested in 1 company to date.
Latest investment by Zhejiang Ausun was on December 1st 2020. Zhejiang Ausun invested in IMPACT Therapeutics in their $50M Series C round (EV/Revenue multiple available to Pro users).
Latest Investments by Zhejiang Ausun
| Description | IMPACT Therapeutics is a Pudong-headquartered biopharmaceutical company developing first-in-class targeted cancer therapies based on synthetic lethality. Focused on DNA damage response pathways, it advances clinical-stage assets including tusamitamab ravtansine and josonalide for solid tumors. The firm collaborates with partners like Bayer and Eli Lilly, with operations in China and Europe since its 2010 founding. |
| HQ Country | |
| HQ City | Nanjing |
| Deal Date | 1 Dec 2020 |
| Round | Series C |
| Raised | $50M |
| Investors | AJ Asset Management; China Summit Capital; Lilly Asia Ventures; Shanghai Junshi; West Fountain Global Fund; Zhejiang Ausun; Zhenji Capital |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Zhejiang Ausun investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zhejiang Ausun
| When was Zhejiang Ausun founded? | Zhejiang Ausun was founded in 2010. |
| Where is Zhejiang Ausun headquartered? | Zhejiang Ausun is headquartered in China. |
| Is Zhejiang Ausun publicly listed? | Yes, Zhejiang Ausun is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Zhejiang Ausun? | Zhejiang Ausun trades under 603229 ticker. |
| When did Zhejiang Ausun go public? | Zhejiang Ausun went public in 2017. |
| Who are competitors of Zhejiang Ausun? | Zhejiang Ausun main competitors include Phibro Animal Health, HBM Holdings, Guilin Sanjin, Avalyn Pharma, MedinCell, Youcare Pharmaceutical, Marksans Pharma, TOWA Pharmaceutical, Bio-Thera Solutions, Aktis Oncology. |
| What is the current market cap of Zhejiang Ausun? | Zhejiang Ausun's current market cap is $1B. |
| What is the current revenue of Zhejiang Ausun? | Zhejiang Ausun's last fiscal year revenue is $117M. |
| What is the current EV/Revenue multiple of Zhejiang Ausun? | Current revenue multiple of Zhejiang Ausun is 9.1x. |
| Is Zhejiang Ausun profitable? | No, Zhejiang Ausun is not profitable. |
| How many companies Zhejiang Ausun has acquired to date? | Zhejiang Ausun hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Zhejiang Ausun has invested to date? | As of June 2026, Zhejiang Ausun has invested in 1 company. |
| What was the last Zhejiang Ausun investment? | On 1st December 2020 Zhejiang Ausun invested in IMPACT Therapeutics, participating in a $50M Series C round, alongside AJ Asset Management, China Summit Capital, Lilly Asia Ventures, Shanghai Junshi, West Fountain Global Fund, and Zhenji Capital. |
| In what companies Zhejiang Ausun invested in? | Zhejiang Ausun invested in IMPACT Therapeutics. |
See public comps similar to Zhejiang Ausun
Lists including Zhejiang Ausun
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
